Received Oct 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Vaccine stored outside recommended conditions and administered to patient; This non-serious case was reported by the other health professional via call center representative and described the occurrence of incorrect storage of drug in a patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. Co-suspect products included HAV (Havrix) for prophylaxis. On an unknown date, the patient received Boostrix and Havrix. On an unknown date, an unknown time after receiving Boostrix and Havrix, the patient experienced incorrect storage of drug (Verbatim: Vaccine stored outside recommended conditions and administered to patient). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 29-SEP-2025 There was a temperature excursion of Boostrix and Havrix as 31.8 degree Fahrenheit for 1.5 hours. The reporter said that She was not sure and needed to check if the vaccines were administered. The batch number was not provided upon follow- up with the reporter.